ACB three-lens brief
Evidence-based stock research on ACB. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both. · Trading at 2% of its 52-week range — deep in the lower band.
- Trading at 2% of its 52-week range — deep in the lower band.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Underperforming SPY by 22.6pp over 30 days.
- Currently unprofitable on a trailing basis — no P/E multiple available.
- Earnings scheduled 2026-08-05.
ACB closed at $2.70 (-0.05%) as of 2026-07-10. Market cap: $167.16M. Price is below the 50-day MA and below the 200-day MA. Concerns: trading at 2% of its 52-week range — deep in the lower band.; 50-day MA below 200-day MA (death-cross regime); price below both.. Last quarter: Revenue $84.82M, net income -$56.90M, free cash flow $8.99M. Watching for: 2026-08-05 earnings release (25 days out).
Why three lenses on ACB, not one.
A single reasoning model has blind spots it doesn’t know about. We examine ACBacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/ACB" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath ACB brief"></iframe>